This shows that the occurrence of aPL antibodies, an important criterion for the diagnosis of APS, is therefore obviously much more drastic in APS than in COVID-19 patients indicating that the prevalence of acute COVID-19 with measurable aPL antibodies is not at all on the level of a distinctive clinical picture of an APS. The gene discussed is FASLG; the disease is COVID-19.